Here are the DEF 14A proxy statements from Kyntra Bio, Inc. (KYNB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow KYNB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KYNB filings page.
Kyntra Bio, Inc. will hold its 2026 Annual Meeting of Stockholders as a virtual-only live audio webcast on June 12, 2026 at 8:00 a.m. Pacific Time. Stockholders as of the April 16, 2026 record date, when 4,048,112 common shares were outstanding, may vote.
Stockholders are asked to elect Class III director Michael Kauffman, M.D., Ph.D., approve on an advisory basis the compensation of named executive officers, and ratify PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026.
The five-member Board includes four independent directors and is led by independent Chair James A. Schoeneck. Committees oversee audit, compensation, and governance, including enterprise risk management, cybersecurity, and ESG programs. Non-employee directors receive cash retainers and stock options under the 2024 Equity Incentive Plan.